Search

Your search keyword '"Guggiari, E"' showing total 96 results
Start Over Author "Guggiari, E"
96 results on '"Guggiari, E"'

1. Sirolimus-based graft-versus-host disease prophylaxis promotes the in vivo expansion of regulatory T cells and permits peripheral blood stem cell transplantation from haploidentical donors

Author

Peccatori, J, Forcina, A, Clerici, D, Crocchiolo, R, Vago, L, Stanghellini, M T L, Noviello, M, Messina, C, Crotta, A, Assanelli, A, Marktel, S, Olek, S, Mastaglio, S, Giglio, F, Crucitti, L, Lorusso, A, Guggiari, E, Lunghi, F, Carrabba, M, Tassara, M, Battaglia, M, Ferraro, A, Carbone, M R, Oliveira, G, Roncarolo, M G, Rossini, S, Bernardi, M, Corti, C, Marcatti, M, Patriarca, F, Zecca, M, Locatelli, F, Bordignon, C, Fleischhauer, K, Bondanza, A, Bonini, C, and Ciceri, F

Published
2015
Full Text
View/download PDF

5. VENTILATION HETEROGENEITY OF PERIPHERAL AIRWAYS (SACIN*VT) ASSESSED BY NITROGEN MULTIPLE BREATH WASHOUT (N2-MBW) IS AN ACCURATE AND SENSITIVE MARKER OF BRONCHIOLITIS OBLITERANS - THE SAN RAFFAELE EXPERIENCE IN HSCT SETTING: PH-P360

Author

De Giacomi, F., Orsini, A., Guggiari, E., Corti, C., Calcaterra, B., Forcina, A., Perini, T., Piemontese, S., Pavesi, F., Levati, G., Milani, R., Peccatori, J., Bernardi, M., Assanelli, A., Bonini, C., Ciceri, F., Cremona, G., and Lupo-Stanghellini, M.

Published
2014

6. T CELL DEPLETED HAPLOIDENTICAL STEM CELL TRANSPLANTATION FOLLOWED BY ADD-BACKS OF SUICIDE-GENE MODIFIED DONOR T-CELLS OFFERS LONG TERM SURVIVAL FREE OF IMMUNE SUPPRESSION TREATMENT: A 7 YEARS FOLLOW-UP IN 56 PATIENTS: PH-O084

Author

Lupo-Stanghellini, M. T., Greco, R., Oliveira, G., Peccatori, J., Marcatti, M., Guggiari, E., Lunghi, F., Marktel, S., Giglio, F., Bondanza, A., Malerba, A., Trinca, S., Corti, C., Bernardi, M., Lambiase, A., Bordignon, C., Bonini, C., and Ciceri, F.

Published
2014

9. Rapamycin-based GvHD prophylaxis after T-cell replete unmanipulated haploidentical peripheral stem cell transplantation for advanced leukaemias: preliminary results of the TrRaMM study: O171

Author

Peccatori, J., Clerici, D., Forcina, A., Messina, C., Stanghellini, Lupo M.T., Noviello, M., Valtolina, V., Giorgiani, G., Crocchiolo, R., Marcatti, M., Mastaglio, S., Assanelli, A., Guggiari, E., Crotta, A., Gattillo, S., Rossini, S., Corti, C., Bernardi, M., Locatelli, F., Bonini, C., and Ciceri, F.

Published
2009

16. Treosulfan based reduced toxicity conditioning followed by allogeneic stem cell transplantation in patients with myelofibrosis

Author

Claudiani S., Marktel S., Piemontese S., Assanelli A., Lupo-Stanghellini M. T., Carrabba M., Guggiari E., Giglio F., De Freitas T., Marcatti M., Bernardi M., Corti C., Peccatori J., Lunghi F., Ciceri F., Claudiani, S., Marktel, S., Piemontese, S., Assanelli, A., Lupo-Stanghellini, M. T., Carrabba, M., Guggiari, E., Giglio, F., De Freitas, T., Marcatti, M., Bernardi, M., Corti, C., Peccatori, J., Lunghi, F., and Ciceri, F.

Subjects
Male, Transplantation Conditioning, bone marrow transplantation, Middle Aged, Allografts, Disease-Free Survival, Survival Rate, Primary Myelofibrosis, hematopoietic stem cell transplantation, reduced-toxicity conditioning, Humans, Female, myeloproliferative disease, Unrelated Donors, treosulfan, Busulfan, Vidarabine, Aged, Stem Cell Transplantation
Abstract

Allogeneic transplantation is the only potentially curative strategy for myelofibrosis, even in the era of new drugs that so far only mitigate symptoms. The choice to proceed to allogeneic transplantation is based on several variables including age, disease phase, degree of splenomegaly, donor availability, comorbidities and iron overload. These factors, along with conditioning regimen and time to transplantation, may influence the outcome of ASCT. We report 14 patients affected by myelofibrosis with a median age of 57 years (range, 41–76) receiving a treosulfan-fludarabine based reduced toxicity conditioning. Patients (pts) received a stem cell transplantation from an HLA identical (n = 10) or matched unrelated donor (n = 4). All pts had a complete myeloablation followed by engraftment and in 12 out of 13 evaluated pts donor chimerism was 100% at 1 month. In most cases a reduction of splenomegaly and a reduction (or resolution) of bone marrow fibrosis was observed. After a median follow-up of 39 months (range, 3–106), the 3-year probability of overall survival and disease free survival was 54 +/− 14% and 46 +/− 14%, respectively. The cumulative incidence of non-relapse mortality at 2 years was 39 +/− 15%. Causes of non-relapse mortality were: infection (n = 2), GvHD (n = 2) and haemorrhage (n = 1). We can conclude that a treosulfan and fludarabine based conditioning has a potent myeloablative and anti-disease activity although non-relapse mortality remains high in this challenging clinical setting. Copyright © 2014 John Wiley & Sons, Ltd.

Published
2016

17. Secondary solid tumors after allogeneic stem cell transplantation: active surveillance in long term follow-up

Author

Lupo-Stanghellini MT, Assanelli A, Greco R, Giglio F, Mastaglio S, Morelli M, Pavesi F, Sala E, Brambilla M, Piemontese S, Vago L, Messina C, Dalto SC, Francesca L, Perini T, Girlanda S, Malerba A, Marcatti M, Guggiari E, Marktel S, Carrabba M, Lunghi F, Bernardi M, Bonini C, Corti C, Peccatori J, Ciceri F, Lupo-Stanghellini, Mt, Assanelli, A, Greco, R, Giglio, F, Mastaglio, S, Morelli, M, Pavesi, F, Sala, E, Brambilla, M, Piemontese, S, Vago, L, Messina, C, Dalto, Sc, Francesca, L, Perini, T, Girlanda, S, Malerba, A, Marcatti, M, Guggiari, E, Marktel, S, Carrabba, M, Lunghi, F, Bernardi, M, Bonini, C, Corti, C, Peccatori, J, and Ciceri, F

Published
2016

18. Standardized care of long-term survivors after allogeneic stem cell transplantation: a cross-sectional 1-year evaluation in 249 adults

Author

Lupo-Stanghellini MT, Orsini A, Mastaglio S, Girlanda S, Perini T, Brambilla M, Tassara M, Lorentino F, Piemontese S, Forcina A, Vago L, Pavesi F, Sala E, Malerba A, Marcatti M, Guggiari E, Marktel S, Assanelli A, Carrabba M, Lunghi F, Bernardi M, Peccatori J, Corti C, Ciceri F, Lupo-Stanghellini, Mt, Orsini, A, Mastaglio, S, Girlanda, S, Perini, T, Brambilla, M, Tassara, M, Lorentino, F, Piemontese, S, Forcina, A, Vago, L, Pavesi, F, Sala, E, Malerba, A, Marcatti, M, Guggiari, E, Marktel, S, Assanelli, A, Carrabba, M, Lunghi, F, Bernardi, M, Peccatori, J, Corti, C, and Ciceri, F

Published
2015

19. THE ITALIAN MASTOCYTOSIS REGISTRY: THE FIRST FIVE YEARS

Author

Merante, S., Neri, I., Magliacane, D., Fortina, A. Belloni, Ingeborg, F., Pastorello, E. A., Mauro, M., Minelli, R., Difonzo, E. D. Elisa, Guggiari, E., Peserico, A., Romani, I., Bocchia, M., Fontana, E., Di Nuzzo, S., Elli, E. M., Elena, C., Virginia Valeria Ferretti, Brazzelli, V., Ciccocioppo, R., Di Stefano, M., Bossi, G., Boveri, E., Virdi, A., and Triggiani, M.

Published
2015

20. Romiplostim for post-transplantation failure of platelet recovery

Author

Marktel S, Pavesi F, Tassara M, Guggiari E, Crotta A, Carrabba M, Claudiani S, Malato S, Assanelli A, Bernardi M, Marcatti M, Corti C, CICERI , FABIO, Marktel, S, Pavesi, F, Tassara, M, Guggiari, E, Crotta, A, Carrabba, M, Claudiani, S, Malato, S, Assanelli, A, Bernardi, M, Marcatti, M, Corti, C, and Ciceri, Fabio

Published
2012

21. Anidulafungin primary antifungal prophylaxis in 36 high-risk haematological patients undergoing haematopoietic stem cell transplantation

Author

Matteazzi F, Levati G, Assanelli A, Mastaglio S, Carrabba M, Guggiari E, Greco R, Forcina A, Tassara M, Lupo Stanghellini M, Vago L, Gentner B, Corti C, Peccatori J., CICERI , FABIO, Matteazzi, F, Levati, G, Assanelli, A, Mastaglio, S, Carrabba, M, Guggiari, E, Greco, R, Forcina, A, Tassara, M, Lupo Stanghellini, M, Vago, L, Gentner, B, Corti, C, Ciceri, Fabio, and Peccatori, J.

Published
2012

23. Successful use of plerixafor in combination with G-CSF to achieve mega-doses of progenitors from healthy donors for haploidentical T-depleted stem cell transplantation

Author

Bellio L, Gattillo S, Guggiari E, Parisi C, Tassara M, Malabarba L, Zambelli M, Coppola M, Greco R, Assanelli A, Corti C, Peccatori J, Rossini S, Marktel S., CICERI , FABIO, Bellio, L, Gattillo, S, Guggiari, E, Parisi, C, Tassara, M, Malabarba, L, Zambelli, M, Coppola, M, Greco, R, Assanelli, A, Corti, C, Peccatori, J, Rossini, S, Ciceri, Fabio, and Marktel, S.

Published
2012

24. Treosulfan-based conditioning regimen for allo-SCT in 283 patients: co-morbidity index and disease status are predictors of outcomes

Author

Lupo Stanghellini MT, Corti C, Marcatti M, Sala E, Crotta A, Messina C, Forno B, Coppola M, Assanelli A, Clerici D, Guggiari E, Lunghi F, Carrabba M, Camba L, Giglio F, Tassara M, Mastaglio S, Greco R, Calbi V, Malato S, Marktel S, Bernardi M, CICERI, FABIO, Peccatori J., BONINI , MARIA CHIARA, Lupo Stanghellini, Mt, Corti, C, Marcatti, M, Sala, E, Crotta, A, Messina, C, Forno, B, Coppola, M, Assanelli, A, Clerici, D, Guggiari, E, Lunghi, F, Carrabba, M, Camba, L, Giglio, F, Tassara, M, Mastaglio, S, Greco, R, Calbi, V, Malato, S, Marktel, S, Bonini, MARIA CHIARA, Bernardi, M, Ciceri, Fabio, and Peccatori, J.

Published
2011

25. Monitoring of Wilms' Tumor Gene 1 Levels Predict Early Relapse After Allogeneic Hematopoietic Stem Cells Transplantation in Patients with High Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome

Author

Sala E, Messina C, Tresoldi C, Carrabba M, Tassara M, Crotta A, Vignati A, Guggiari E, Mattarucchi R, Assanelli A, Peccatori J, Corti C, Bernardi M., CICERI , FABIO, Sala, E, Messina, C, Tresoldi, C, Carrabba, M, Tassara, M, Crotta, A, Vignati, A, Guggiari, E, Mattarucchi, R, Assanelli, A, Peccatori, J, Corti, C, Ciceri, Fabio, and Bernardi, M.

Published
2011

26. Implementation of an alternative donor is a prerequisite for a good intention-to-treat performance in patients in need of allogeneic transplantation: analysis of 361 patients

Author

Lupo Stanghellini MT, Marcatti M, Assanelli A, Greco R, Lunghi F, Crotta A, Guggiari E, Carrabba M, Camba L, Clerici D, Malato S, Forno B, Marktel S, Coppola M, Bitetti C, Corti C, Bernardi M, Peccatori J, BONINI , MARIA CHIARA, BORDIGNON, CLAUDIO, CICERI, FABIO, Lupo Stanghellini, Mt, Marcatti, M, Assanelli, A, Greco, R, Lunghi, F, Crotta, A, Guggiari, E, Carrabba, M, Camba, L, Clerici, D, Malato, S, Forno, B, Marktel, S, Coppola, M, Bitetti, C, Bonini, MARIA CHIARA, Bordignon, Claudio, Corti, C, Bernardi, M, Peccatori, J, and Ciceri, Fabio

Published
2010

27. Timing and rate of success in transplant of matched unrelated donor (MUD) searches through bone marrow donors worldwide (BMDW): the case of San Raffaele Institute in 2006-2009

Author

Forno B, Mazzi B, Zino E, Lupo Stanghellini MT, Vago L, Guggiari E, Coppola M, Piemontese S, Claudiani S, Lunghi F, Marktel S, Bernardi M, Corti C, Peccatori J, CICERI, FABIO, Fleischhauer K, Marcatti M., BONINI , MARIA CHIARA, Forno, B, Mazzi, B, Zino, E, Lupo Stanghellini, Mt, Vago, L, Guggiari, E, Coppola, M, Piemontese, S, Claudiani, S, Lunghi, F, Marktel, S, Bernardi, M, Corti, C, Bonini, MARIA CHIARA, Peccatori, J, Ciceri, Fabio, Fleischhauer, K, and Marcatti, M.

Published
2010

28. Bone marrow morphology and cytogenetics in donors provide additional safety in allogeneic haematopoietic stem cell transplantation: results in 460 healthy candidates

Author

Lupo Stanghellini MT, Gattillo S, Ronchi P, Guggiari E, Fomo B, Sala E, Lorentino F, Malato S, Bruno Ventre M, Piemontese S, Girlanda S, Tassara M, Zino E, Mazzi B, Bellio L, Malabarba L, Corti C, Bernardi M, Peccatori J, Fleischhauer K, Marcatti M, Rossini S., CICERI , FABIO, Lupo Stanghellini, Mt, Gattillo, S, Ronchi, P, Guggiari, E, Fomo, B, Sala, E, Lorentino, F, Malato, S, Bruno Ventre, M, Piemontese, S, Girlanda, S, Tassara, M, Zino, E, Mazzi, B, Bellio, L, Malabarba, L, Corti, C, Bernardi, M, Peccatori, J, Fleischhauer, K, Marcatti, M, Ciceri, Fabio, and Rossini, S.

Published
2010

29. Monitoring of Willms' tumour gene 1 transcripts in AML and MDS patients can predict early relapse after allogeneic haematopoietic stem cell transplantation

Author

Messina C, Bernardi M, Tresoldi C, Stanghellini MTL, Crotta A, Tassara M, Girlanda S, Coppola M, Piemontese S, Greco R, Malato S, Forno B, Assanelli A, Clerici D, Mastaglio S, Giglio F, Bruno Ventre M, Lunghi F, Guggiari E, Carrabba M, Marcatti M, Corti C, BONINI , MARIA CHIARA, Fleischhauer K, Peccatori J, BORDIGNON, CLAUDIO, CICERI , FABIO, Messina, C, Bernardi, M, Tresoldi, C, Stanghellini, Mtl, Crotta, A, Tassara, M, Girlanda, S, Coppola, M, Piemontese, S, Greco, R, Malato, S, Forno, B, Assanelli, A, Clerici, D, Mastaglio, S, Giglio, F, Bruno Ventre, M, Lunghi, F, Guggiari, E, Carrabba, M, Marcatti, M, Corti, C, Bonini, MARIA CHIARA, Fleischhauer, K, Peccatori, J, Bordignon, Claudio, and Ciceri, Fabio

Published
2010

30. Rapamycin-based GvHD prophylaxis after T-cell replete unmanipulated haploidentical peripheral stem cell transplantation for advanced leukaemias: preliminary results of the TrRaMM study

Author

Peccatori J, Clerici D, Forcina A, Messina C, Lupo Stanghellini MT, Noviello M, Valtolina V, Giorgiani G, Crocchiolo R, Marcatti M, Mastaglio S, Assanelli A, Guggiari E, Crotta A, Gattillo S, Rossini S, Corti C, Bernardi M, Locatelli F, CICERI, FABIO, BONINI , MARIA CHIARA, Peccatori, J, Clerici, D, Forcina, A, Messina, C, Lupo Stanghellini, Mt, Noviello, M, Valtolina, V, Giorgiani, G, Crocchiolo, R, Marcatti, M, Mastaglio, S, Assanelli, A, Guggiari, E, Crotta, A, Gattillo, S, Rossini, S, Corti, C, Bernardi, M, Locatelli, F, Bonini, MARIA CHIARA, and Ciceri, Fabio

Published
2009

31. SECOND ALLOGENEIC STEM CELL TRANSPLANTATION AS SALVAGE TREATMENT IN RELAPSED HAEMATOLOGICAL MALIGNANCIES: FEASIBILITY AND OUTCOME IN 26 PATIENTS

Author

Stanghellini MTL, Assanelli AA, Crocchiolo R, Clerici D, Tassara M, Calbi V, Bernardi M, Marcatti M, Corti C, Carrabba MG, Lunghi F, Guggiari E, Camba L, BONINI , MARIA CHIARA, Peccatori J, CICERI , FABIO, Stanghellini, Mtl, Assanelli, Aa, Crocchiolo, R, Clerici, D, Tassara, M, Calbi, V, Bernardi, M, Marcatti, M, Corti, C, Carrabba, Mg, Lunghi, F, Guggiari, E, Camba, L, Bonini, MARIA CHIARA, Peccatori, J, and Ciceri, Fabio

Published
2009

32. Factors affecting successful mobilization with plerixafor: an Italian prospective survey in 215 patients with multiple myeloma and lymphoma

Author

Lanza, F., Lemoli, R. M., Olivieri, A., Laszlo, D., Martino, M., Specchia, G., Pavone, V., Imola, M., Pasini, A., Milone, G., Scortechini, I., Todisco, E., Guggiari, E., Cascavilla, N., Martinelli, G., Rambaldi, A., and Bosi, A.

Subjects
Adult, Male, Benzylamines, Receptors, CXCR4, Adolescent, Lymphoma, Cyclams, NO, Aged, Blood Component Removal, Chemoradiotherapy, Data Collection, Female, Hematopoietic Stem Cell Mobilization, Heterocyclic Compounds, Humans, Italy, Leukapheresis, Middle Aged, Multiple Myeloma, Platelet Count, Predictive Value of Tests, Prospective Studies, Young Adult, Receptors, CXCR4
Abstract

Although the efficacy of plerixafor in peripheral blood stem cell (PBSC) mobilization has been explored in several studies, factors associated with successful plerixafor mobilization after administration of granulocyte-colony-stimulating factor (G-CSF), with or without chemotherapy, have not been investigated. We analyzed data on PBSC mobilization from a large Italian database of lymphoma and myeloma plerixafor-treated patients.Two endpoints were established to define successful mobilization: patients with at least 2 × 10(6) CD34+ cells/kg collected by three leukapheresis procedures and patients achieving a peak count of at least 20 × 10(6) CD34+ cells/L during mobilization.Plerixafor achieved successful mobilization in both predicted (n = 64) and proven poor mobilizers (PMs; n = 143), classified according to the Gruppo Italiano Trapianto di Midollo Osseo (GITMO) criteria. Successful mobilization was independent of type of mobilization (steady state or chemotherapy); age; sex; disease; number or type of chemotherapy regimens preceding plerixafor; radiation therapy; prior treatment with melphalan, carmustine, lenalidomide, and radioimmune conjugates; and laboratory variables. Multivariate analysis identified previous fludarabine treatment and premobilization platelet count as predictors of successful mobilization.This large, prospective, nationwide study confirmed plerixafor efficacy for mobilizing PBSCs when added to G-CSF with or without chemotherapy. Plerixafor can overcome negative effects of most predictors of poor mobilization to achieve satisfactory harvest both in predicted and proven PM.

Published
2014

34. Feasibility and efficacy of allogeneic stem cell transplantation for refractory or relapsed myelodysplastic syndrome and secondary acute myeloid leukaemia: a single-centre experience

Author

Tassara M, Crotta A, Peccatori J, Stanghellini ML, Corti C, Calbi V, Assanelli A, Servida P, Guggiari E, Lunghi F, Bernardi M., CICERI , FABIO, Tassara, M, Crotta, A, Peccatori, J, Stanghellini, Ml, Corti, C, Calbi, V, Assanelli, A, Servida, P, Guggiari, E, Lunghi, F, Ciceri, Fabio, and Bernardi, M.

Published
2007

36. Allogeneic stem cell transplantation in patients with poor prognosis myelodysplastic syndrome (MDS) or secondary acute myeloid leukaemia (sAML): results from a single centre experience

Author

Tassara M, Crotta A, Peccatori J, Assanelli A, Corti C, Guggiari E, Stanghellini MTL, Servida P, Ruggeri A, Calbi V, CICERI , FABIO, Bernardi M., Tassara, M, Crotta, A, Peccatori, J, Assanelli, A, Corti, C, Guggiari, E, Stanghellini, Mtl, Servida, P, Ruggeri, A, Calbi, V, Ciceri, Fabio, and Bernardi, M.

Published
2007

38. Effect of bortezomib on theAutonomic nervous system

Author

Crocchiolo R, Ferrari S, Calbi V, Marcatti M, Guggiari E, Servida P, Bernardi M, Del Carro U, Bonini C, Tresoldi M, Peccatori J, Natali Sora MG, CICERI , FABIO, Crocchiolo, R, Ferrari, S, Calbi, V, Marcatti, M, Guggiari, E, Servida, P, Bernardi, M, Del Carro, U, Bonini, C, Tresoldi, M, Peccatori, J, Ciceri, Fabio, and Natali Sora, Mg

Published
2006

39. Foscarnet is an effective pre-emptive treatment of cytomegalovirus reactivation after T-cell depleted haploidentical stem cell transplantation

Author

Lupo Stanghellini MT, Lunghi F, Corti C, Guggiari E, Crocchiolo R, Roccia TR, Brurnoventre M, Servida P, Bernardi M, Peccatori J, Crippa F, BONINI , MARIA CHIARA, BORDIGNON, CLAUDIO, CICERI , FABIO, Lupo Stanghellini, Mt, Lunghi, F, Bonini, MARIA CHIARA, Corti, C, Guggiari, E, Crocchiolo, R, Roccia, Tr, Brurnoventre, M, Servida, P, Bernardi, M, Peccatori, J, Crippa, F, Bordignon, Claudio, and Ciceri, Fabio

Published
2006

40. Sirolimus-based graft-versus-host disease prophylaxis promotes the in vivo expansion of regulatory T cells and permits peripheral blood stem cell transplantation from haploidentical donors

Author

Peccatori, J., Forcina, A., Clerici, D., Crocchiolo, R., Vago, L., Stanghellini, M. T. L., Noviello, M., Messina, C., Crotta, A., Assanelli, A., Marktel, S., Olek, S., Mastaglio, S., Giglio, F., Crucitti, L., Lorusso, A., Guggiari, E., Lunghi, F., Carrabba, M., Tassara, M., Battaglia, M., Ferraro, A., Carbone, M. R., Oliveira, G., Roncarolo, M. G., Rossini, S., Bernardi, M., Corti, C., Marcatti, M., Patriarca, F., Zecca, M., Locatelli, Franco, Bordignon, C., Fleischhauer, K., Bondanza, A., Bonini, C., Ciceri, F., Locatelli F. (ORCID:0000-0002-7976-3654), Peccatori, J., Forcina, A., Clerici, D., Crocchiolo, R., Vago, L., Stanghellini, M. T. L., Noviello, M., Messina, C., Crotta, A., Assanelli, A., Marktel, S., Olek, S., Mastaglio, S., Giglio, F., Crucitti, L., Lorusso, A., Guggiari, E., Lunghi, F., Carrabba, M., Tassara, M., Battaglia, M., Ferraro, A., Carbone, M. R., Oliveira, G., Roncarolo, M. G., Rossini, S., Bernardi, M., Corti, C., Marcatti, M., Patriarca, F., Zecca, M., Locatelli, Franco, Bordignon, C., Fleischhauer, K., Bondanza, A., Bonini, C., Ciceri, F., and Locatelli F. (ORCID:0000-0002-7976-3654)

Abstract

Hematopoietic stem cell transplantation (HSCT) from human leukocyte antigen (HLA) haploidentical family donors is a promising therapeutic option for high-risk hematologic malignancies. Here we explored in 121 patients, mostly with advanced stage diseases, a sirolimus-based, calcineurin-inhibitor-free prophylaxis of graft-versus-host disease (GvHD) to allow the infusion of unmanipulated peripheral blood stem cell (PBSC) grafts from partially HLA-matched family donors (TrRaMM study, Eudract 2007-5477-54). Conditioning regimen was based on treosulfan and fludarabine, and GvHD prophylaxis on antithymocyte globulin Fresenius (ATG-F), rituximab and oral administration of sirolimus and mycophenolate. Neutrophil and platelet engraftment occurred in median at 17 and 19 days after HSCT, respectively, and full donor chimerism was documented in patients' bone marrow since the first post-transplant evaluation. T-cell immune reconstitution was rapid, and high frequencies of circulating functional T-regulatory cells (Treg) were documented during sirolimus prophylaxis. Incidence of acute GvHD grade II-IV was 35%, and occurrence and severity correlated negatively with Treg frequency. Chronic GvHD incidence was 47%. At 3 years after HSCT, transpant-related mortality was 31%, relapse incidence 48% and overall survival 25%. In conclusion, GvHD prophylaxis with sirolimus-mycophenolate-ATG-F-rituximab promotes a rapid immune reconstitution skewed toward Tregs, allowing the infusion of unmanipulated haploidentical PBSC grafts.

Published
2015

47. Sirolimus-based graft-versus-host disease prophylaxis promotes the in vivo expansion of regulatory T cells and permits peripheral blood stem cell transplantation from haploidentical donors

Author

Peccatori, J, primary, Forcina, A, additional, Clerici, D, additional, Crocchiolo, R, additional, Vago, L, additional, Stanghellini, M T L, additional, Noviello, M, additional, Messina, C, additional, Crotta, A, additional, Assanelli, A, additional, Marktel, S, additional, Olek, S, additional, Mastaglio, S, additional, Giglio, F, additional, Crucitti, L, additional, Lorusso, A, additional, Guggiari, E, additional, Lunghi, F, additional, Carrabba, M, additional, Tassara, M, additional, Battaglia, M, additional, Ferraro, A, additional, Carbone, M R, additional, Oliveira, G, additional, Roncarolo, M G, additional, Rossini, S, additional, Bernardi, M, additional, Corti, C, additional, Marcatti, M, additional, Patriarca, F, additional, Zecca, M, additional, Locatelli, F, additional, Bordignon, C, additional, Fleischhauer, K, additional, Bondanza, A, additional, Bonini, C, additional, and Ciceri, F, additional

Published
2014
Full Text
View/download PDF

48. Effect of Related and Unrelated Donor Haematopoietic Stem-Cell Transplantation on Outcome in Adults With High Risk Hematological Disease: An intention-to-treat Analysis of 410 Patients at a Single Center Institution

Author

Lupo-Stanghellini, M.T., primary, Forno, B., additional, Marcatti, M., additional, Bitetti, C., additional, Coppola, M., additional, Assanelli, A., additional, Greco, R., additional, Lunghi, F., additional, Tassara, M., additional, Guggiari, E., additional, Carrabba, M., additional, Matteazzi, F., additional, Camba, L., additional, Clerici, D., additional, Malato, S., additional, Marktel, S., additional, Bonini, C., additional, Bordignon, C., additional, Corti, C., additional, Bernardi, M., additional, Peccatori, J., additional, and Ciceri, F., additional

Published
2011
Full Text
View/download PDF

49. P156 Allogeneic stem cell transplantation in patients with poor prognosis myelodysplastic syndrome (MDS) or secondary acute myeloid leukaemia (sAML): results from a single centre experience

Author

Tassara, M., primary, Crotta, A., additional, Peccatori, J., additional, Assanelli, A., additional, Corti, C., additional, Guggiari, E., additional, Lupo Stanghellini, M.T., additional, Servida, P., additional, Ruggeri, A., additional, Calbi, V., additional, Ciceri, F., additional, and Bernardi, M., additional

Published
2007
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results